Description

Traicor (fenofibrate) coated tablets 145 mg. №20

Ingredients

Each coated tablet contains 145 mg of fenofibrate.

Dosage

The recommended dosage is one tablet daily with a meal.

Indications

Traicor tablets are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Contraindications

Do not use Traicor tablets if you have severe renal impairment, including patients receiving dialysis; pre-existing gallbladder disease; nursing or pregnant women; or known hypersensitivity to fenofibrate.

Directions

Swallow the tablet whole with water. Do not crush, chew, or break the tablet.

Scientific Evidence

Fenofibrate, the active ingredient in Traicor tablets, has been extensively studied for its lipid-modifying effects. Research published in the Journal of Clinical Lipidology demonstrated that fenofibrate significantly reduced triglycerides and LDL-C levels while increasing HDL-C levels in patients with dyslipidemia.

Additional Information

It is important to monitor liver function tests during therapy with fenofibrate due to the potential risk of liver abnormalities. Additionally, patients should be advised to report any unexplained muscle pain, tenderness, or weakness, as fenofibrate may cause myopathy.

In clinical trials, fenofibrate has shown to be effective in reducing cardiovascular events in patients with dyslipidemia. A study published in the New England Journal of Medicine found that fenofibrate therapy was associated with a significant reduction in the risk of coronary events in patients with type 2 diabetes.